Bibliography
- Chawla J. Migraine headache. Available from: http://emedicine.medscape.com/article/1142556-print [Last Accessed 14 April 2009]
- Diener HC, Dodick DW, Goadsby PJ, et al. Identification of negative predictors of pain-free response to triptans: analysis of the eletriptan database. Cephalagia 2008;28:35-40
- Tepper SJ, Stillman MJ. Clinical and preclinical rationale for CGRP-receptor antagonists in the treatment of migraine. Headache 2008;48:1259-68
- Olesen J, Diener H-C, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 for the acute treatment of migraine. N Engl J Med 2004;350:1104-10
- Paone DV, Shaw AW, Nguyen DN, et al. Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl]-4-(-2oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridine-1-yl)piperidine-1-carboxamide (MK-0974). J Med Chem 2007;50:5564-7
- Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 2008;70:1304-12
- Ho TW, Ferrari MD, Rodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial. Lancet 2008;372:2115-23
- Gladstone JP, Gawel M. Newer formulations of the triptans: advances in migraine management. Drugs 2003;63:2285-305
- Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia 2002;22:633-58
- Brandes JL, Kudrow D, Stark SR, et al. Sumitriptan-naproxen for acute treatment of migraine; a randomized trial. JAMA 2007;297:1443-54